Pediatric Malignancies

Eric K. Ring; G. Yancey Gillespie; Gregory K. Friedman

doi:10.1016/B978-0-323-54948-6.00010-X

Pediatric Malignancies

Eric K. Ring, G. Yancey Gillespie, Gregory K. Friedman

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Pediatric cancer is an extremely diverse group of diseases in a patient population that varies widely by age, development, and immunocompetence. Although advances in standard therapy and supportive care have improved outcomes for children with cancer, survival rates remain extremely poor for treatment refractory patients, and survivors carry a significant burden of long-term morbidities. Immunosuppressive checkpoint molecules that downregulate the host immune system and allow for tumor escape are demonstrating increasing efficacy in adult cancer trials. However, there are limited data describing these molecules and their inhibitors in pediatric cancer. In this chapter, we review the current knowledge on immune checkpoint molecules and their inhibitors in pediatric cancer and discuss unique challenges in this diverse patient population.

Original language	English (US)
Title of host publication	Immune Checkpoint Inhibitors in Cancer
Publisher	Elsevier
Pages	193-204
Number of pages	12
ISBN (Electronic)	9780323549486
ISBN (Print)	9780323549509
DOIs	https://doi.org/10.1016/B978-0-323-54948-6.00010-X
State	Published - Jan 1 2019
Externally published	Yes

Keywords

Checkpoint proteins
CTLA-4
IDO
Immunotherapy
PD-1
Pediatric brain tumors
Pediatric solid tumors

ASJC Scopus subject areas

Medicine(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/B978-0-323-54948-6.00010-X

Cite this

@inbook{7946d839c4574a76a966ecf849226d3f,

title = "Pediatric Malignancies",

abstract = "Pediatric cancer is an extremely diverse group of diseases in a patient population that varies widely by age, development, and immunocompetence. Although advances in standard therapy and supportive care have improved outcomes for children with cancer, survival rates remain extremely poor for treatment refractory patients, and survivors carry a significant burden of long-term morbidities. Immunosuppressive checkpoint molecules that downregulate the host immune system and allow for tumor escape are demonstrating increasing efficacy in adult cancer trials. However, there are limited data describing these molecules and their inhibitors in pediatric cancer. In this chapter, we review the current knowledge on immune checkpoint molecules and their inhibitors in pediatric cancer and discuss unique challenges in this diverse patient population.",

keywords = "Checkpoint proteins, CTLA-4, IDO, Immunotherapy, PD-1, Pediatric brain tumors, Pediatric solid tumors",

author = "Ring, {Eric K.} and Gillespie, {G. Yancey} and Friedman, {Gregory K.}",

year = "2019",

month = jan,

day = "1",

doi = "10.1016/B978-0-323-54948-6.00010-X",

language = "English (US)",

isbn = "9780323549509",

pages = "193--204",

booktitle = "Immune Checkpoint Inhibitors in Cancer",

publisher = "Elsevier",

address = "Netherlands",

}

TY - CHAP

T1 - Pediatric Malignancies

AU - Ring, Eric K.

AU - Gillespie, G. Yancey

AU - Friedman, Gregory K.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Pediatric cancer is an extremely diverse group of diseases in a patient population that varies widely by age, development, and immunocompetence. Although advances in standard therapy and supportive care have improved outcomes for children with cancer, survival rates remain extremely poor for treatment refractory patients, and survivors carry a significant burden of long-term morbidities. Immunosuppressive checkpoint molecules that downregulate the host immune system and allow for tumor escape are demonstrating increasing efficacy in adult cancer trials. However, there are limited data describing these molecules and their inhibitors in pediatric cancer. In this chapter, we review the current knowledge on immune checkpoint molecules and their inhibitors in pediatric cancer and discuss unique challenges in this diverse patient population.

AB - Pediatric cancer is an extremely diverse group of diseases in a patient population that varies widely by age, development, and immunocompetence. Although advances in standard therapy and supportive care have improved outcomes for children with cancer, survival rates remain extremely poor for treatment refractory patients, and survivors carry a significant burden of long-term morbidities. Immunosuppressive checkpoint molecules that downregulate the host immune system and allow for tumor escape are demonstrating increasing efficacy in adult cancer trials. However, there are limited data describing these molecules and their inhibitors in pediatric cancer. In this chapter, we review the current knowledge on immune checkpoint molecules and their inhibitors in pediatric cancer and discuss unique challenges in this diverse patient population.

KW - Checkpoint proteins

KW - CTLA-4

KW - IDO

KW - Immunotherapy

KW - PD-1

KW - Pediatric brain tumors

KW - Pediatric solid tumors

UR - http://www.scopus.com/inward/record.url?scp=85137545171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85137545171&partnerID=8YFLogxK

U2 - 10.1016/B978-0-323-54948-6.00010-X

DO - 10.1016/B978-0-323-54948-6.00010-X

M3 - Chapter

AN - SCOPUS:85137545171

SN - 9780323549509

SP - 193

EP - 204

BT - Immune Checkpoint Inhibitors in Cancer

PB - Elsevier

ER -

Pediatric Malignancies

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this